Nykredit A S Buys New Position in Zoetis Inc. $ZTS

Key Points

• Nykredit A/S acquired 139,745 Zoetis shares during the second quarter, worth approximately $10.04 million. Institutional investors collectively own 92.8% of the company.
• Zoetis reported quarterly EPS of $1.87, slightly beating estimates of $1.85, while revenue of $2.47 billion fell short of forecasts and declined 0.2% year over year.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $101.08, while the stock recently traded near $71.53—close to its 52-week low.

Nykredit A S bought a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 139,745 shares of the company's stock, valued at approximately $10,042,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. J. Stern & Co. LLP lifted its stake in shares of Zoetis by 12,431.2% during the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company's stock valued at $3,028,423,000 after buying an additional 23,877,416 shares during the period. BlackRock Inc. grew its stake in Zoetis by 10.8% in the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company's stock worth $2,833,453,000 after acquiring an additional 3,845,869 shares during the period. Geode Capital Management LLC grew its stake in Zoetis by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company's stock worth $1,420,294,000 after acquiring an additional 189,235 shares during the period. Norges Bank acquired a new position in Zoetis in the 4th quarter valued at $734,425,000. Finally, Deutsche Bank AG raised its holdings in Zoetis by 19.1% in the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company's stock valued at $699,331,000 after acquiring an additional 891,921 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

NYSE ZTS opened at $71.53 on Monday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis Inc. has a 1-year low of $71.00 and a 1-year high of $148.79. The firm has a market capitalization of $29.56 billion, a P/E ratio of 11.78, a P/E/G ratio of 1.67 and a beta of 0.73. The business's 50-day simple moving average is $75.31 and its 200-day simple moving average is $89.74.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter last year, the firm posted $1.76 earnings per share. Zoetis's revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts predict that Zoetis Inc. will post 6.2 EPS for the current year.

Wall Street Analyst Weigh In

ZTS has been the topic of several analyst reports. Barclays decreased their price objective on Zoetis from $136.00 to $85.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 1st. Stifel Nicolaus cut their price objective on shares of Zoetis from $85.00 to $80.00 and set a "hold" rating on the stock in a report on Thursday, August 20th. Citigroup decreased their target price on shares of Zoetis from $112.00 to $96.00 and set a "buy" rating on the stock in a research report on Tuesday, August 11th. Zacks Research downgraded shares of Zoetis from a "hold" rating to a "strong sell" rating in a report on Monday, August 10th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Zoetis from $130.00 to $115.00 and set an "overweight" rating for the company in a research report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, Zoetis presently has an average rating of "Hold" and a consensus price target of $101.08.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company's product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.